Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease

NCT04109300 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Diseases
Ulcerative Colitis
Crohn Disease

Interventions

GENETIC: HLADQA1*05A>G screening
OTHER: Standard of Care

Sponsor

Western University, Canada